1. Scrip
  2. >>Leadership
  3. >>Executives On The Move

Asia Executives To Watch: Betta CEO Quits To Nurture Drug Startups

 
• By Brian Yang

Betta CEO Yinxiang Wang is moving on to focus on a drug discovery incubator while another board director, Zai Lab's Samantha Du, has also resigned. Executive changes are also underway at Japanese drug startup PeptiDream.

chess

Yinxiang Wang is one of three co-founders of the Hangzhou-based Betta Pharmaceuticals Co. Ltd., along with Leiming Ding. He directly contributed to developing Betta's single and best-selling product Conmana (icotinib) for small-cell lung cancer.

The drug is now competing head-on with Iressa (gefitinib) from AstraZeneca PLC and Tarceva (erlotinib) from Roche

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Executives On The Move

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.

Executives On The Move: Ten CMOs And Three CEOs and CFOs Each Among This Week’s Changes

Recent moves in the industry include C-suite changes at Dyne Therapeutics, City Therapeutics and ProQR Therapeutics, plus Madrigal Pharmaceuticals acquires chief medical officer from Novartis.

More from Leadership

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.